[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ras-g12d-mutated-nsclc\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ras-g12d-mutated-nsclc":55},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100528549",false,"NCT06162221","Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC","A Platform Study of RAS(ON) Inhibitors in Patients With RAS-Mutated Non-Small Cell Lung Cancer (NSCLC)","Inclusion criteria:\n\nAll Patients (unless otherwise noted):\n\n* ≥ 18 years of age\n* ECOG PS is 0 to 1\n* Adequate organ function as outlined by the study\n* Received prior standard therapy appropriate for tumor type and stage\n* Must have pathologically documented, locally advanced or metastatic KRAS G12C-mutated solid tumor malignancy (not amenable to curative surgery) (Subprotocol A)\n* Must have pathologically documented, locally advanced or metastatic RAS-mutated NSCLC (Subprotocol B)\n* Must have pathologically documented, locally advanced or metastatic RAS G12D-mutated NSCLC (Subprotocol C and Subprotocol D)\n\nExclusion criteria:\n\nAll Patients:\n\n* Primary central nervous system (CNS) tumors\n* Impaired gastrointestinal (GI) function that may significantly alter the absorption of RMC drugs\n* Major surgery \\\u003C 28 days of first dose\n* Active or history of interstitial lung disease (ILD) or pneumonitis requiring steroids\n\nOther inclusion\u002Fexclusion criteria may apply.","ALL","18 Years",{"count":18,"type":19},616,"ESTIMATED","INTERVENTIONAL",[22,23],"PHASE1","PHASE2","The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors as a monotherapy or combined with Standard(s) of Care (SOC) or with each other.\n\nThe first four subprotocols include the following:\n\nSubprotocol A: RMC-6291 +\u002F- RMC-6236 + SOC Subprotocol B: RMC-6236 + SOC Subprotocol C: RMC-9805 +\u002F- RMC-6236 + SOC Subprotocol D: RMC-9805",[26,27,28,29,30],"Non-Small Cell Lung Cancer, NSCLC","KRAS, NRAS, HRAS-mutated NSCLC","KRAS G12C-mutated Solid Tumors, Lung Cancer","Lung Cancer Stage IV, Advanced Solid Tumor, Cancer","RAS G12D-mutated NSCLC",[32,33,34,35,36,37,38,39,40,41],"NSCLC","KRAS G12C","RAS Mutation","KRAS G12X","Non-Small Cell Lung Cancer","Lung Cancer","Lung Cancer Stage IV","Advanced Solid Tumor","Cancer","RAS G12D","RECRUITING","2026-06-25",{"date":45,"type":46},"2026-06-30","ACTUAL",{"date":48,"type":46},"2024-01-18",{"date":50,"type":19},"2028-12",{"name":52,"class":53},"Revolution Medicines, Inc.","INDUSTRY",93,""]